Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice

C. Fava, G. Rege-Cambrin, I. Dogliotti, M. Cerrano, P. Berchialla, M. Dragani, G. Rosti, F. Castagnetti, G. Gugliotta, B. Martino, C. Gambacorti-Passerini, E. Abruzzese, C. Elena, P. Pregno, A. Gozzini, I. Capodanno, M. Bergamaschi, M. Crugnola, M. Bocchia, S. GalimbertiD. Rapezzi, A. Iurlo, D. Cattaneo, R. Latagliata, M. Breccia, M. Cedrone, M. Santoro, M. Annunziata, L. Levato, F. Stagno, F. Cavazzini, N. Sgherza, V. Giai, L. Luciano, S. Russo, P. Musto, G. Caocci, F. Sorà, F. Iuliano, F. Lunghi, G. Specchia, F. Pane, D. Ferrero, M. Baccarani, G. Saglio

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1589-1596
Number of pages8
JournalHaematologica
Volume104
Issue number8
DOIs
Publication statusPublished - 2019

Keywords

  • alpha interferon
  • bosutinib
  • dasatinib
  • imatinib
  • nilotinib
  • ponatinib
  • protein tyrosine kinase inhibitor
  • adult
  • Article
  • cancer chemotherapy
  • cancer patient
  • chronic myeloid leukemia
  • chronopharmacology
  • clinical practice
  • drug intoxication
  • drug safety
  • drug withdrawal
  • feasibility study
  • female
  • follow up
  • human
  • Italian (citizen)
  • leukemia relapse
  • leukemia remission
  • major clinical study
  • male
  • observational study
  • oncologist
  • pregnancy
  • retreatment
  • retrospective study
  • shared decision making
  • treatment duration
  • treatment failure
  • treatment response
  • treatment withdrawal

Cite this